Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although biologic agents used for the treatment of rheumatoid arthritis are approved for first-line use, they are actua
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although biologic agents used for the treatment of rheumatoid arthritis are approved for first-line use, they are actua
是世界一流的研究和咨询公司之一，着眼于制药和卫生保健问题，该公司发现虽然用于治疗类风湿性关节炎的生物制剂虽然已被批准为一线用药，而实际上用一线药物治疗的病人中不到3%使用生物制剂，二线药物治疗的病人中不到4%。